chrisvoncsefalvay/vaers-outcomes huggingface dataset:
"REASON FOR ADMISSION Patient is a 82-year-old male with past medical history of BPH, hypertension, atrial fibrillation, possible dementia who is admitted here for petechiae due to obstructive uropathy/urinary retention, COVID asymptomatic. He has been medically stable for some days, AKI resolved, no hematuria. His foley will be removed at SNF on the morning of 8/29 prior to urology eval.   AKI due to obstructive uropathy/urinary retention, resolved Continue Foley.   Urology saw the patient, continue foley until follow-up with Urology outpatient for cystoscopy and voiding trial. His foley can be removed on 8/29 morning at SNF.  Patient is also on keflex, per prior chart review continue until follow up with urology.  Patient is stale for discharge today to SNF.   Hematuria, resolved Eliquis resumed   Hypokalemia Monitor and replace.   Hypophosphatemia Monitor and replace   A Fib/A Flutter with RVR, resolved Continue eliquis Continie BB, added cardizem on cardio recs.   Non sustained V tach overnight 16 run Asymptomatic. KCL replaced overnight, check Mag this am.   BPH Proscar and flomax"
EMS brought pt to hosp after pt being unresponsive and in cardiac arrest; CPR initiated; Patient intubated and sedated in the field; achieved and pt transported to hosp; family states pt has been fatigued x 2wks, sleeping more, up at night coughing; test positive for COVID in ED; pt's condition continued to decline; renal failure worsened; pt was extubated and died in the hospital
GRANDMOTHER REPORTED THAT CHILD HAD DEVELOPED RAISED SWOLLEN AREA TO LEFT LEG (SITE WHERE PCV7) WAS ADMININSTERED.  ADVISED TO ADMINISTER WARMING PACKS TO SITE AT LEAST 4 TIMES PER DAY.  MD DID NOT WANT TO SEE CLIENT.
Received updated covid booster and a week and a half later a clot.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 38-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 08Jan2023 at 14:00 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 38 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Factor five" (unspecified if ongoing). Concomitant medication(s) included: PRADAXA (ongoing). Vaccination history included: Covid-19 vaccine (Dose: 01, UNKNOWN MANUFACTURER), for COVID-19 Immunization; Covid-19 vaccine (Dose: 02, UNKNOWN MANUFACTURER), for COVID-19 Immunization; Covid-19 vaccine (Dose: 03, 1st Booster; UNKNOWN MANUFACTURER), for COVID-19 Immunization. The following information was reported: THROMBOSIS (prolonged hospitalization, medically significant) with onset 12Jan2023, outcome "recovered with sequelae", described as "Received updated covid booster and a week and a half later a clot.". The events "received updated covid booster and a week and a half later a clot." required physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: Nasopharyngeal swab: (21Oct2022) Negative, notes: At home. Therapeutic measures were taken as a result of thrombosis.  Clinical course: Prior to the vaccination, the patient was not diagnosed with COVID. The patient had been taking Pradaxa for 6 years. Received updated covid booster and a week and a half later a clot. He had factor five, so he was prone to developing clots. Treatment received as Heprin to dissolve the clot and heightened dose.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Information has been received from a RN concerning a 51 year old female phlebotomist with a low rubella titer, reoccurring achy joints and a pollen allergy and a history of lyme disease and thyroid surgery (1980) who on 17Jul03 was vaccinated with a dose of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (second generation). Concomitant therapy included levothyroxine Na (Synthroid) and fexofenadine hydrochloride (+) pseudosphedrine hydrochloride (ALLEGRA-D). A few days post vaccination, the pt developed pain in both hands. During the week of 28Jul03, the pt notified the reporter, the employee health nurse, of the symptoms including numbness with occasional swelling of both hands. Unspecified medical attention was sought. On 05Aug03, the pt was seen and the symptoms continued. It was reported that the pt had no history of arthritis of hands but she was a phlebotomist at the hospital and a part time manicurist. The pt did not know if she was vaccinated with measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (second generation) in the past. Additional information has been requested.
Herpes of the eye....He used to get this when he was 1-3 and after an antiviral medication he stopped getting it and hasn't had it for about 9 years until after he got this vaccine.  We put ointment on it and it took about a month to go away.
Severe chills, fever, body ache, arm twitching, head aches, and hallucinations. I was almost unconscious Tuesday night.
10OCT stiff-swelling, pain-sl temp, very restless sleep;11OCT swollen & pain, can't move arm; 2 1/2" wide 3-4" long; 13OCT redness, nodule same, more movement in arm; red blotches, very itchy;
Pt recvd DPT/HIB/OPV @ clinic & @ 2PM mom said pt awoke from nap & was blue & splotchy & t99; pt had a shaking chill but no sz noted; pt had unusual cry about 1 hr; t102 R;
Patient is a 57 year old woman works as a cleaner with PMHx morbid obesity, HTN (on amlodipine, metoprolol, triamterene-HCTZ), CKD3 (baseline Cr 1.1-1.2) who presented to the ED on 5/28 with worsening shortness of breath, cough with yellow sputum, fatigue, and weakness, found to be COVID-19 positive. She was subsequently admitted to the MICU for acute hypoxic respiratory failure.    At baseline, she is independent in all ADLs and works as a cleaner at an office building. She got the first dose of the pfizer COVID vaccine series 5/10, scheduled for second dose 6/2. She lives with her husband and nephew in a house with additional family members who live downstairs. She says she only really goes to work and always wears a mask while there. Her daughter (lives downstairs) helps with grocery shopping. No recent travel or sick contacts that she is aware of.   She was in her usual state of health until 5/22 when she said she started to feel poorly. She had increasing shortness of breath over the next few days with worsening fatigue and cough to the extent that she was considering calling off from work. She continued to feel poorly and decided it was time to go to the ED on Friday, 5/28.    Today, she says she is feeling better and is less short of breath. She still has coughing that is occasionally productive for clear sputum. No fevers, chills, lightheadedness/dizziness, chest pain, abdominal pain, nausea, vomiting, diarrhea. Her appetite is improved, and she is eating and drinking better today.   Patient is a 57 year old female with PMHx obesity, HTN, CKD3 who presented to the ED with shortness of breath, cough, fatigue, found to have COVID-19. In the ED, she was hypoxic requiring increasing amounts of oxygen, ultimately with 40% FiO2 via Ventimask and HFNC when admitted to the MICU. CT chest with GGO/patchy consolidation in posterior lung areas and bases as is typically seen with COVID-19 infection.   She has been started on remdesivir and dexamethasone and is now requiring HFNC for oxygen supplementation. Likely her single dose of vaccine has helped to lessen her disease severity. She meets criteria for addition of tocilizumab.    Recommendations: - Continue dexamethasone and remdesivir - Can add tocilizumab - Health care maintenance: Screened for HIV 2009, HCV 2018, HBV 2018. Last TDAP 2015.    I saw and examined the patient. I strongly agree with the resident/fellow's findings and plan of care.  Patient with risk factors for severe Covid including obesity underlying kidney disease and hypertension presents with fever fatigue malaise and infiltrates on chest CT a little over 2 weeks after initial mRNA vaccination Denies any anosmia Agree with current treatment plan including dexamethasone and 5 days of remdesivir duction and maintenance and okay for tocilizumab as she is less than 24 hours into the ICU Other health maintenance up-to-date HIV negative remote hepatitis negative I will ask lab for cycle threshold out of curiosity as she has been vaccinated which likely has mitigated severe disease   Explained to patient in detail and questions answered. Spoke to ICU team please call back if questions
This case was reported by a physician and described the occurrence of myalgia in a 23 year old female pt who received Engerix-B. On 3/9/04, the pt received the 3rd dose of Engerix-B in her right arm. Approx. 1 day later, on 310/04, the pt experienced myalgia and cephalgia. She was seen at a physician's office. The events resolved on 3/11/04. The reporting physician considered the events to probably be related to vaccination with Engerix-B.
This spontaneous report was received from a pharmacist concerning a patient of unknown age and gender. There was no information about the patient's concurrent conditions, medical history or concomitant medication. On 22-MAY-2018, the patient was vaccinated with ZOSTAVAX lot # M041087 with expiration date of 03-JAN-2018 for prophylaxis (dose, route of administration and anatomical location were not reported). This was supported as per the expiry memo. No adverse effects reported.
Swelling, redness, rash and irritation to left upper arm from shoulder down to elbow.
Breakthrough COVID positive on 4/12/21 Became symptomatic headache and congestion on 4/12/21 Healthcare worker tested in routine staff testing in LTC
headache; fever of 99 degrees/ fever goes to 100 degrees; joints started to sour/sourness increased; This is a spontaneous report from a contactable consumer (patient) reported for herself. A 45-years-old non pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EN6203), via an unspecified route of administration, administered in Arm Left on 17Mar2021 at 15:30/03:30 PM (at the age of 45-years-old) as dose 2, single for COVID-19 immunisation. The patient had no known allergies. No other medical history and no concomitant medications (in two weeks) were reported. Historical vaccine included bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EL3247), via an unspecified route of administration, administered in Arm Left on 25Feb2021 at 10:45 AM (at the age of 45-years-old) as dose 1, single for COVID-19 immunisation. Facility type vaccine was other. The patient did not take other vaccine in four weeks. The patient had no covid prior vaccination, was not covid tested post vaccination. The patient stated that the next morning, on 18Mar2021 at 08:00 AM, she started to feel a headache. Then by noon time (unspecified), she got a fever of 99 degrees and my joints started to sour. By evening, the fever got to 100 degrees and the sourness increased. Treatment taken was with a tablet of Advil. Then on 19Mar2021, she woke up, all the symptoms were done, and she was back to normal. The patient underwent lab test and procedure which included Fever: 99 degrees on 18Mar2021 (noon time), Fever: 100 degrees on 18Mar2021 (By evening). The events outcome was resolved on 19Mar2021.  No follow-up attempts were possible. No further information was expected.
She states her vision went black for 10 seconds. She then had a mild headache after the event and had some cold sweats.
pt felt extreme itching/ burning/ stinging on her back. There were small blisters, redness and inflammation. Pt has been applying Aveno Exczema, benedrly topical. The topical helped a little bit. and Pt  recieved Valtrex prescription that She tried and helped a little bit but made her tired and Dizzie. Pt is still complaining of rash, redness and inflamation
cold-like symptoms; This is a spontaneous report received from a contactable reporter(s) (Pharmacist) from medical information team for a Pfizer sponsored program.  A 55 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as single dose for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: INFLUENZA LIKE ILLNESS (non-serious), outcome "unknown", described as "cold-like".  Additional information: Caller was a pharmacist who states that a 55 year old female patient received her first dose of the Pfizer BioNTech COVID-19 vaccine 13 days ago and since then has been experiencing "cold-like" symptoms. Caller states that this patient came into to report how she was feeling and caller decided to do a COVID-19 test on her. He would like to know if he could potentially see a positive result on the test because she has received her first dose of the vaccine.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Chest pain, no definite pericarditis, but less than 1 week after vaccine
Ha,malaise,  body aches, nausea , vomiting,diarrhea,, bilateral ear aches, swollen glands under chin,
Fever, chills, mild headache, heart palpitations, sharp fleeting pain under ribs.
Headache - 24 hours Joint aches - hips, knees, wrists, neck - 24/36 hours Fatigue - 3 days
pt recv vax;swelling,redness&warmth at inject site&baby had high pitched cry x 2hrs;tx w/ dph per mom;not to give any more pertussis;
Second dose of Pfizer COVID-19 vaccine was administered 14 days after the first dose.
Fever; shaking chills; Headache; Fatigue; This is a spontaneous report from a non-contactable consumer, the patient. A 33-year-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. On an unknown date, the patient experienced fever, shaking chills, headache, and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events fever, shaking chills, headache, and fatigue was resolved on an unknown date.  No follow-up attempts are possible, information about lot/batch number cannot be obtained. No further information is expected.
Shot on 07/19/02. Rash started 07/20/02 into see doctor. 07/23/02 saw doctor rash on face urticaria allergic rash Prevnar ix no more Prevnar per doctor.
did not get my 2nd shot; made me nervous; This is a spontaneous report from a contactable consumer (patient. A female patient of unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number: not reported, Expiration date: not reported) via an unspecified route of administration on an unspecified date as dose 1, single for COVID-19 immunization. The patient medical history included COVID-19 on an unspecified date in Mar2021. Concomitant medications were not reported. On an unspecified date in Apr2021, patient stated any of the my refrigerator magnets would stick to my injection site for up to 72 hours, it made me nervous so I did not get my 2nd shot. Patient also reported any of the my refrigerator magnets would stick to my injection site for up to 72 hours. What is in the vaccine that makes it stick to her arm?. Will I be sicker with it because I have gone past the 3-6 week period?" Is there any information on magnetic effects at the injection site after receiving vaccination with the Pfizer-BioNTech COVID-19 vaccine. It was reported that We are not aware of any properties of the content of the vaccine that would suggest magnetic effects at the site of injection. In fact, the U.S. Centers for Disease Control and Prevention  has specifically stated that all COVID-19 vaccines are free from metals such as iron, nickel, cobalt, lithium, rare earth alloys or any manufactured products such as microelectronics, electrodes, carbon nanotubes, or nanowire semiconductors. As of 30Apr2021, a search of our safety surveillance database for Pfizer-BioNTech COVID-19 vaccine revealed no spontaneous reports of magnetic properties at injection site since the market introduction (including emergency use authorization) of Pfizer-BioNTech COVID-19 vaccine. Also, a search of the published medical literature on 19May2021 failed to identify relevant information on this topic. Therefore, we are not aware of any information regarding events of magnetic effects at the site of injection. The outcome of events was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
sweats; not feeling awesome; feels like glass in her bones; whenever she moves it hurts; chills; felt sick to the stomach; This spontaneous case was reported by a consumer and describes the occurrence of NIGHT SWEATS (sweats), MALAISE (not feeling awesome), BONE PAIN (feels like glass in her bones; whenever she moves it hurts), CHILLS (chills) and NAUSEA (felt sick to the stomach) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported.).    On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Jan-2021, the patient experienced NIGHT SWEATS (sweats), MALAISE (not feeling awesome), BONE PAIN (feels like glass in her bones; whenever she moves it hurts), CHILLS (chills) and NAUSEA (felt sick to the stomach). At the time of the report, NIGHT SWEATS (sweats), MALAISE (not feeling awesome), BONE PAIN (feels like glass in her bones; whenever she moves it hurts), CHILLS (chills) and NAUSEA (felt sick to the stomach) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication details were not reported by the reporter. Treatment details not reported by the reporter.
Patient states she got a large red lump.  She got medical care on 10/9 at Clinic.  The lump itched and was painful if she laid on it.  Dr prescribed cephlexin to cover possible cellulitis.
Improperly stored vaccine involved in a temperature excursion was administered to a patient; No additional AE reported; This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported.  On an unknown date, the patient was vaccinated with an improperly stored of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) for prophylaxis (lot # W006595 has been verified to be a valid lot number haemophilus b conjugate vaccine (meningococcal protein conjugate), expiration date reported and establish 10-OCT-2024) (strength, dose, route of administration and anatomical location were not provided).  The temperature of storage and time frame of the excursion were 57.49° Fahrenheit (F) for 1 hour and 45 minutes respectively.  If a digital data logger was involved was not reported.  The vaccines did not experience a previous temperature excursion.  No adverse event reported.
Initial unsolicited report received from other non-healthcare professional on 27-Oct-2017. This case was linked with 2017SA211778, 2017SA244729, 2017SA244847, 2017SA244854, 2017SA244856. This case involves an male patient of unknown age who was vaccinated with a 0.5 ml single dose of FLUZONE injection (Lot number: UI856AB, expiry date, dose in series, route and site of administration were not reported) on an unknown date. The patient's medical history and concomitant medications were not reported. On an unknown date, following the vaccination, the patient developed a severe localized reaction, injection site swelled to baseball size, was very red and painful. The patient's laboratory data and corrective treatment were not reported. The event's outcome was not reported. List of documents held by sender: none.
Extreme fatigue, fever then five days later arm is still very red and swollen and sore. The redness is traveling
Face is very numb and it is kind of drooping to right side; Face is very numb and it is kind of drooping to right side; This is a spontaneous report from a contactable consumer (patient). A patient of unspecified age and gender received the first dose of bnt162b2 (BNT162B2 reported as PFIZER-BIONTECH COVID-19 VACCINE; unknown lot number and expiration date), at unknown vaccination age via an unspecified route of administration on an unspecified date in 2021 as a single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient reported that "I am having side effects. My face is very numb, and it is kind of drooping to right side." The patient inquired as to what to do or where to go (to the hospital?). The patient mentioned that "I guess so, I am just going to go to the hospital." The patient received the vaccine on Wednesday (unspecified date in 2021) and this happened last night (05Feb2021). The outcome of the events was unknown.  Information about the Lot/batch number has been requested.
Moderna COVID-19 Vaccine EUA  Fever 100.1, chills, entire body aches, injection site extreme pain - took Tylenol regularly under arm/breast area lump felt - Dr is having me apply ice and watch to see if it decreases because it occurred on same arm that I received the injection.  Wants to wait until after 2nd dose to see if it goes away
no additional adverse event reported; the patient was administered a dose of improperly stored VARIVAX; This spontaneous report was received from a nurse referring to a 12 months old patient of unknown gender. The patient's medical history, concurrent conditions, concomitant medications, drug allergies/ reactions were not reported.  On 02-APR-2020, the patient was administered improperly stored varicella virus vaccine live (Oka/Merck) (VARIVAX) (lot # S002393, expiration date: 23-JAN-2021, strength, dose and route were unknown) for prophylaxis (product storage error). The sterile diluent used to reconstitute the vaccine did not undergo a temperature excursion. The vaccine was exposed to minus 9 degrees Celsius to 8 degrees Celsius (minus 6.8 degrees Celsius) for 6 hours. There was no previous temperature excursion. The data logger was involved. No additional adverse event was reported.
Woke up sick on 11/21/02, day after shot, felt sick and weak and warm. Stayed in bed for 2 days. Took Tylenol x2. Also had upset stomach; didn't vomit. Also had 3 years ago and got sick like that (flu shot).
Caller reported an Improperly stored administered PROQUAD; This spontaneous report was received from a nurse, referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, previous drug reactions or allergies and concomitant medications were not reported.   On 14-SEP-2020, the patient was vaccinated with an improperly stored dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (rHA) (PROQUAD) (strength, vaccination scheme, route of administration and anatomical site of vaccination were not reported; lot number T013540, expiration date 17-OCT-2021) given as prophylaxis.  The vaccine administered experienced a temperature excursion between 6 Fahrenheit (F) and 14 F (Average temperature of 11.7 F) for 25 minutes, as recorded by a data logger. There was no previous temperature excursion reported. No additional information was reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2009USA008941: US-009507513-2009USA008944: US-009507513-2009USA008968: US-009507513-2009USA009041: US-009507513-2009USA009321: